ARTICLE | Financial News
Durect plunges on Chronogesic news
July 22, 2004 7:00 AM UTC
DRRX dropped $1.45 (53%) to $1.27 on 4.1 million shares on Thursday following Wednesday's post-market news that it will not resume Phase III trials of its Chronogesic pain product this year. The compa...